Optimizing the Delivery of GI Care in Transgender and Gender-Diverse Communities

Article Type
Changed
Fri, 05/02/2025 - 09:49
Display Headline

Optimizing the Delivery of GI Care in Transgender and Gender-Diverse Communities

Click to view more from Gastroenterology Data Trends. 

References
  1. Jones JM. LGBTQ+ identification in U.S. rises to 9.3%. Gallup.com website. February 20, 2025. Accessed March 4, 2025. https://news.gallup.com/poll/656708/lgbtq-identification-rises.aspx.
  2. Newman KL, Vélez C, Paul S, Radix AE, Streed CG Jr, Targownik LE. Research Considerations in Digestive and Liver Disease in Transgender and Gender-Diverse Populations. Gastroenterology. 2023;165(3):523-528.e1. doi:10.1053/j.gastro.2023.07.011
  3. Vélez C, Newman KL, Paul S, Berli JU, Tangpricha V, Targownik LE. Approaching Digestive Health Care in Transgender and Gender-Diverse Communities. Clin Gastroenterol Hepatol. 2024;22(3):441-447.e2. doi:10.1016/j.cgh.2023.12.001
  4. Condray CD, Newman KL, Chedid VG. Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States. Nat Rev Gastroenterol Hepatol. 2024;21(10):662-663. doi:10.1038/s41575-024-00975-4
  5. Tsai C, Abdelhalim S, Wong S-Y, Xie X, Agrawal M, Keefer LA. Trauma-Informed Care in Gastroenterology: A Survey of Provider Attitudes, Knowledge, and Skills. Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00953-4. doi:10.1016/j.cgh.2024.09.015
  6. Newman KL, Chedid VG, Boden EK. A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals. Gastroenterology. 2023;164(6):866-871. doi:10.1053/j.gastro.2022.11.048
  7. Hassan B, Suchan A, Brown M, Kishan A, Liang F, Truta B. The Impact of Hormone Therapy on Inflammatory Bowel Disease in Transgender and Nonbinary Individuals. Inflamm Bowel Dis. 2024 Oct 16:izae236. doi:10.1093/ibd/izae236
  8. Elhence H, Dodge JL, Kahn JA, Lee BP. Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study. Am J Gastroenterol. 2024;119(12):2455-2461. doi:10.14309/ajg.0000000000002907
  9. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694-1702. doi:10.1002/ijc.34850
  10. Nash R, Ward KC, Jemal A, Sandberg DE, Tangpricha V, Goodman M. Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data. Cancer Epidemiol. 2018;54:1-6. doi:10.1016/j.canep.2018.02.008
Author and Disclosure Information

Kira Newman, MD, PhD
Clinical Assistant Professor, Department of
Medicine, Division of Gastroenterology and
Hepatology, University of Michigan,
Ann Arbor, Michigan

Disclosures: Received research grant from: Pfizer

Publications
Topics
Author and Disclosure Information

Kira Newman, MD, PhD
Clinical Assistant Professor, Department of
Medicine, Division of Gastroenterology and
Hepatology, University of Michigan,
Ann Arbor, Michigan

Disclosures: Received research grant from: Pfizer

Author and Disclosure Information

Kira Newman, MD, PhD
Clinical Assistant Professor, Department of
Medicine, Division of Gastroenterology and
Hepatology, University of Michigan,
Ann Arbor, Michigan

Disclosures: Received research grant from: Pfizer

Click to view more from Gastroenterology Data Trends. 

Click to view more from Gastroenterology Data Trends. 

References
  1. Jones JM. LGBTQ+ identification in U.S. rises to 9.3%. Gallup.com website. February 20, 2025. Accessed March 4, 2025. https://news.gallup.com/poll/656708/lgbtq-identification-rises.aspx.
  2. Newman KL, Vélez C, Paul S, Radix AE, Streed CG Jr, Targownik LE. Research Considerations in Digestive and Liver Disease in Transgender and Gender-Diverse Populations. Gastroenterology. 2023;165(3):523-528.e1. doi:10.1053/j.gastro.2023.07.011
  3. Vélez C, Newman KL, Paul S, Berli JU, Tangpricha V, Targownik LE. Approaching Digestive Health Care in Transgender and Gender-Diverse Communities. Clin Gastroenterol Hepatol. 2024;22(3):441-447.e2. doi:10.1016/j.cgh.2023.12.001
  4. Condray CD, Newman KL, Chedid VG. Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States. Nat Rev Gastroenterol Hepatol. 2024;21(10):662-663. doi:10.1038/s41575-024-00975-4
  5. Tsai C, Abdelhalim S, Wong S-Y, Xie X, Agrawal M, Keefer LA. Trauma-Informed Care in Gastroenterology: A Survey of Provider Attitudes, Knowledge, and Skills. Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00953-4. doi:10.1016/j.cgh.2024.09.015
  6. Newman KL, Chedid VG, Boden EK. A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals. Gastroenterology. 2023;164(6):866-871. doi:10.1053/j.gastro.2022.11.048
  7. Hassan B, Suchan A, Brown M, Kishan A, Liang F, Truta B. The Impact of Hormone Therapy on Inflammatory Bowel Disease in Transgender and Nonbinary Individuals. Inflamm Bowel Dis. 2024 Oct 16:izae236. doi:10.1093/ibd/izae236
  8. Elhence H, Dodge JL, Kahn JA, Lee BP. Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study. Am J Gastroenterol. 2024;119(12):2455-2461. doi:10.14309/ajg.0000000000002907
  9. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694-1702. doi:10.1002/ijc.34850
  10. Nash R, Ward KC, Jemal A, Sandberg DE, Tangpricha V, Goodman M. Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data. Cancer Epidemiol. 2018;54:1-6. doi:10.1016/j.canep.2018.02.008
References
  1. Jones JM. LGBTQ+ identification in U.S. rises to 9.3%. Gallup.com website. February 20, 2025. Accessed March 4, 2025. https://news.gallup.com/poll/656708/lgbtq-identification-rises.aspx.
  2. Newman KL, Vélez C, Paul S, Radix AE, Streed CG Jr, Targownik LE. Research Considerations in Digestive and Liver Disease in Transgender and Gender-Diverse Populations. Gastroenterology. 2023;165(3):523-528.e1. doi:10.1053/j.gastro.2023.07.011
  3. Vélez C, Newman KL, Paul S, Berli JU, Tangpricha V, Targownik LE. Approaching Digestive Health Care in Transgender and Gender-Diverse Communities. Clin Gastroenterol Hepatol. 2024;22(3):441-447.e2. doi:10.1016/j.cgh.2023.12.001
  4. Condray CD, Newman KL, Chedid VG. Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States. Nat Rev Gastroenterol Hepatol. 2024;21(10):662-663. doi:10.1038/s41575-024-00975-4
  5. Tsai C, Abdelhalim S, Wong S-Y, Xie X, Agrawal M, Keefer LA. Trauma-Informed Care in Gastroenterology: A Survey of Provider Attitudes, Knowledge, and Skills. Clin Gastroenterol Hepatol. 2024 Oct 24:S1542-3565(24)00953-4. doi:10.1016/j.cgh.2024.09.015
  6. Newman KL, Chedid VG, Boden EK. A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals. Gastroenterology. 2023;164(6):866-871. doi:10.1053/j.gastro.2022.11.048
  7. Hassan B, Suchan A, Brown M, Kishan A, Liang F, Truta B. The Impact of Hormone Therapy on Inflammatory Bowel Disease in Transgender and Nonbinary Individuals. Inflamm Bowel Dis. 2024 Oct 16:izae236. doi:10.1093/ibd/izae236
  8. Elhence H, Dodge JL, Kahn JA, Lee BP. Characteristics and Outcomes Among US Commercially Insured Transgender Adults With Cirrhosis: A National Cohort Study. Am J Gastroenterol. 2024;119(12):2455-2461. doi:10.14309/ajg.0000000000002907
  9. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694-1702. doi:10.1002/ijc.34850
  10. Nash R, Ward KC, Jemal A, Sandberg DE, Tangpricha V, Goodman M. Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data. Cancer Epidemiol. 2018;54:1-6. doi:10.1016/j.canep.2018.02.008
Publications
Publications
Topics
Article Type
Display Headline

Optimizing the Delivery of GI Care in Transgender and Gender-Diverse Communities

Display Headline

Optimizing the Delivery of GI Care in Transgender and Gender-Diverse Communities

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Thu, 05/01/2025 - 18:14
Un-Gate On Date
Thu, 05/01/2025 - 18:14
Use ProPublica
CFC Schedule Remove Status
Thu, 05/01/2025 - 18:14
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Overall, 1.3% of US adults identify as transgender or gender-diverse (TGD), with a higher prevalence of TGD-identified people in younger generations.1,2 This finding suggests that all clinicians will provide care to TGD patients.1,2 TGD individuals are more likely to experience health care discrimination than cisgender individuals, resulting in reduced access to and utilization of care.2,3 It is important for health care providers, including gastroenterologists and hepatologists, to create a welcoming and gender-affirming environment—offering single-occupancy handicap-accessible bathrooms, displaying nondiscrimination policies, using inclusive intake forms, and providing training for clinicians to increase knowledge of TGD health needs and address biases.3,4 This type of environment can help reduce negative outcomes for TGD patients seeking care.3,4 Understanding the minority stress model and trauma-informed care approaches can also be useful for caring for TGD patients.2,5 A recent study found that up to 51% of gastrointestinal (GI) providers are not at all familiar with trauma-informed care, highlighting the need for further education.5

High-quality research on GI conditions in TGD populations is limited, and potential proposed biological effects of gender-affirming hormone therapy (GAHT) are still theoretical. Studies have shown that the prevalence of inflammatory bowel disease (IBD) is similar between TGD and cisgender individuals, and that GAHT does not affect flare-ups of IBD, although the sample sizes have been small.6,7 Hepatic conditions such as cirrhosis were shown to be more common in TGD communities, which may be largely due to preventable causes of cirrhosis (e.g., alcohol-associated or viral etiologies) and delayed diagnosis and treatment before progression.8 More research is needed in TGD patients with GI conditions, and best practices for their design and conduct, such as partnering with TGD people, designing studies with cultural humility in mind, using rigorous research methods, and checking for implicit biases in studies, must be followed.2

Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 05/01/2025 - 18:14
Slide Media